Scribe Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Scribe Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Alameda
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SCTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001853921
- EIN
- 82-2157847
Board of directors
-
Behzad Aghazadeh · DirectorSince 2026
-
Benjamin L. Oakes · Director · President, CEOSince 2026
- Since 2026
-
James Dean Watson · DirectorSince 2026
-
Joshua Bleharski · DirectorSince 2026
Chief executives
Benjamin L. Oakes
· President, CEO
Since July 2026
Board connections
2 of this board's directors also sit on 8 other boards.
- via Carl L. Gordon
- via Carl L. Gordon
- via Carl L. Gordon
- via Carl L. Gordon
- via Carl L. Gordon
- via Carl L. Gordon
- via Carl L. Gordon
- via Behzad Aghazadeh
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $71,344,746
- 9 purchases by 6 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 28, 2026 | Behzad Aghazadeh Director, 10% owner, See Remarks | Open-market purchase | +7,905 | $18.25 | $144,266 |
| Jul 27, 2026 | AH Bio Fund II, L.P. 10% owner | Derivative conversion | +2,051,742 | — | — |
| Jul 27, 2026 | Jennifer A. Doudna 10% owner | Derivative conversion | +12,511 | — | — |
| Jul 27, 2026 | Carl L. Gordon Director | Derivative conversion | +348,825 | — | — |
| Jul 27, 2026 | ORBIMED ADVISORS LLC Director | Derivative conversion | +348,825 | — | — |
| Jul 27, 2026 | AH Bio Fund II, L.P. 10% owner | Derivative conversion | +697,650 | — | — |
| Jul 27, 2026 | Carl L. Gordon Director | Open-market purchase | +1,000,000 | $15.00 | $15,000,000 |
| Jul 27, 2026 | ORBIMED ADVISORS LLC Director | Open-market purchase | +1,000,000 | $15.00 | $15,000,000 |
| Jul 27, 2026 | AH Bio Fund II, L.P. 10% owner | Open-market purchase | +333,333 | $15.00 | $4,999,995 |
| Jul 24, 2026 | Behzad Aghazadeh Director, 10% owner, See Remarks | Open-market purchase | +2,333,333 | $15.00 | $34,999,995 |
| Jul 24, 2026 | Behzad Aghazadeh Director, 10% owner, See Remarks | Open-market purchase | +50,000 | $22.31 | $1,115,500 |
| Jul 23, 2026 | Svetlana Lucas Officer (Chief Business Officer) | Open-market purchase | +3,000 | $15.00 | $45,000 |
| Jul 23, 2026 | Parrot David Officer (Chief Financial Officer) | Open-market purchase | +1,333 | $15.00 | $19,995 |
| Jul 23, 2026 | Parrot David Officer (Chief Financial Officer) | Open-market purchase | +1,333 | $15.00 | $19,995 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.